Veradermics reports Q2 2026 results, completes enrollment in female pattern hair loss trial

Veradermics announced financial results for the quarter ended June 30, 2026 and provided updates on its VDPHL01 pipeline in pattern hair loss.

In July 2026, the company reported positive topline results from an open-label Phase 2 trial, Study '207', testing its extended-release oral minoxidil candidate VDPHL01 in women with mild-to-moderate pattern hair loss, with participants dosed at 4.5 mg once or twice daily for six months showing rapid onset of activity and consistent responses in hair count while generally tolerating treatment well.¹ On the trial's efficacy measures, patients gained an average of 22.7 hairs/cm² in the once-daily group and 23.3 hairs/cm² in the twice-daily group in non-vellus target area hair count by month 6, and roughly 89% and 90% of participants respectively reported their hair coverage as "improved" or "much improved" on the trial's rating scale.¹ No treatment-related serious adverse events occurred, and no cardiac-related adverse events of special interest were reported.¹

The company also completed enrollment in Study '306', a Phase 2/3 randomized, double-blind, placebo-controlled trial testing the same two VDPHL01 doses over 52 weeks in 556 women with mild-to-moderate pattern hair loss.¹ The trial's co-primary endpoints are change in non-vellus hair count and patient-reported hair coverage benefit measured at 24 weeks.¹ Veradermics said it expects topline data from Study '306' in the first half of 2027.¹

For its male pattern hair loss programs, the company still expects topline data from the confirmatory Phase 3 Study '304' in the second half of 2026,¹ and twelve-month data from Study '302' are also anticipated in the second half of 2026.¹

On financials, cash, cash equivalents and marketable securities totaled $819.9 million as of June 30, 2026, including proceeds from a follow-on offering completed in the quarter.¹ The company said this cash position is expected to support its operating plans into 2030, including multiple anticipated Phase 3 readouts and a potential commercial launch of VDPHL01, if approved.¹ Net loss for the quarter was $23.5 million, compared with $15.6 million in the same quarter of 2025.¹